Compare Dover Corp (DOV) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Mesoblast Limited — how do they compare? Dover Corp trades at $208.79 (market cap $28.07B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Dover Corp is far larger — about 12.7× Mesoblast Limited's market cap, and Dover Corp pays a 1.01% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DOV | MESO | |
|---|---|---|
Market Cap | $28.07B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $233.31 | $20.96 |
52-Week Low | $161.16 | $12.88 |
Enterprise Value | $29.58B | $2.21B |
Dividend Yield | 1.01% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
